Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search

 


Migco Secures Funding to Develop Migraine Drug

Migco Pharmaceuticals Secures First Round Funding to Develop Migraine Drug

Press release, Migco Pharmaceuticals Ltd, 11-Dec-07, Christchurch, New Zealand: Migco Pharmaceuticals has secured NZ$1m from experienced New Zealand business angel investor, Movac Ltd. The funds will used to obtain approval from the US Food and Drug Administration (FDA) to trial Migco’s compound, codenamed MGX-008, for migraine prevention and to prepare for a formal clinical trial.

Migco was assisted on the shape and size of investment offer by Pacific Channel Ltd, who also advised on investor selection as there was significantly more interest generated than could be accepted.

Further staged funding of NZ$5M will be sought by Migco in six to 12 months to undertake its clinical trials programme.

Migco CEO Larry Stenswick says the funding will allow it to accelerate its drug development programme.

“It is a major step toward our goal of providing an effective treatment for those who suffer from debilitating migraine headaches. We have been very encouraged by results to date, and are especially pleased that the Movac group has invested in our vision. They have a proven track record in supporting successful emerging companies,” says Larry.

Movac director David Beard will join the Migco Board. He says Movac was committed to investing in early stage companies focused on meeting unmet needs.

“We look for the right business plans, management, passion and drive to succeed internationally. Migco Pharmaceuticals meets these criteria,” says David.

About Migco
Migco Pharmaceuticals Ltd is focused on developing and bringing to market innovative therapeutic products that will significantly improve the lives of those suffering from migraine. For more information visit www.migco.co.nz .

About Movac
Movac Ltd is a privately funded and owned angel investor group based in Wellington, New Zealand. We work with entrepreneurs and early stage companies to help them convert their ideas for high growth ventures into profitable, sustainable businesses with the potential to yield good dividend returns. For more information visit www.movac.co.nz .

ENDS

© Scoop Media

 
 
 
 
 
Business Headlines | Sci-Tech Headlines

 

Half A Billion Accounts: Yahoo Confirms Huge Data Breach

The account information may have included names, email addresses, telephone numbers, dates of birth, hashed passwords (the vast majority with bcrypt) and, in some cases, encrypted or unencrypted security questions and answers. More>>

Rural Branches: Westpac To Close 19 Branches, ANZ Looks At 7

Westpac confirms it will close nineteen branches across the country; ANZ closes its Ngaruawahia branch and is consulting on plans to close six more branches; The bank workers union says many of its members are nervous about their futures and asking ... More>>

Interest Rates: RBNZ's Wheeler Keeps OCR At 2%

Reserve Bank governor Graeme Wheeler kept the official cash rate at 2 percent and said more easing will be needed to get inflation back within the target band. More>>

ALSO:

Half Full: Fonterra Raises Forecast Payout As Global Supply Shrinks

Fonterra Cooperative Group, the dairy processor which will announce annual earnings tomorrow, hiked its forecast payout to farmers by 50 cents per kilogram of milk solids as global supply continues to decline, helping prop up dairy prices. More>>

ALSO:

Results:

Meat Trade: Silver Fern Farms Gets Green Light For Shanghai Maling Deal

The government has given the green light for China's Shanghai Maling Aquarius to acquire half of Silver Fern Farms, New Zealand's biggest meat company, with ministers satisfied it will deliver "substantial and identifiable benefit". More>>

ALSO:

Get More From Scoop

 
 
 
 
 
 
 
 
 
Business
Search Scoop  
 
 
Powered by Vodafone
NZ independent news